ArticleCirculation2024
Expansion of Pathogenic Cardiac Macrophages in Immune Checkpoint Inhibitor Myocarditis.
Open access · greenAbstract read
In one paragraph
Article in Circulation, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
124citing papers in PubMed, 3 pooled it
29.7field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed, 3 syntheses or guidelines pooled it, 129 citations in OpenAlex.
- Cardiotoxicity in cancer immunotherapy: a systematic review and global meta-analysis.Journal of translational medicine · 2025Pooled it
- The Cardiotoxicity Risk of Immune Checkpoint Inhibitors Compared with Chemotherapy: A Systematic Review and Meta-analysis of Observational Studies.Cardiovascular toxicology · 2025Pooled it
- Monocyte-related markers as predictors of immune checkpoint inhibitor efficacy and immune-related adverse events: a systematic review and meta-analysis.Cancer metastasis reviews · 2025Pooled it
- Mechanisms of traditional Chinese medicine in enhancing the efficacy and reducing the toxicity of immune checkpoint inhibitorsJournal of enzyme inhibition and medicinal chemistry · 2026Review
- The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact.Journal of immunotherapy and precision oncology · 2026Review
- Cytokine-associated ROS and Ca2+ dysregulation in severe inflammatory cardiomyopathy.Cardiovascular research · 2026Observational
- A serum proteomics-based predictive model for steroid-resistant immune checkpoint inhibitor associated myocarditis.Clinical and translational medicine · 2026Article
- The Cardio-Onco-Immune Axis: immunopathological mechanisms in the cardiac microenvironment of checkpoint inhibitor-induced myocarditis.Acta pharmacologica Sinica · 2026Review
- Review
- Abatacept for steroid-refractory fulminant immune checkpoint inhibitor myocarditis with triple M overlap syndrome: a case report with serial endomyocardial biopsy assessment.European heart journal. Case reports · 2026Article
- Beyond β-Adrenergic Receptor Brake: Compartment-Selective GRK2 Programs from Heart Failure to Cardio-Oncology.Kinases and phosphatases · 2026Article
- Generation of three induced pluripotent stem cell lines from an immune checkpoint inhibitor-induced myocarditis patient and controls.Stem cell research · 2026Article
- Cardiac tertiary immune niches drive immune activation in immune checkpoint inhibitor myocarditis.Science advances · 2026Article
- Endomyocardial Biopsies in the Diagnostic Workup of Immune Checkpoint Inhibitor Associated Myocarditis.Current heart failure reports · 2026Review
- Beyond the Pump: Unravelling Immunometabolic Crosstalk and Organelle Dynamics in Sepsis-Induced Cardiomyopathy.Journal of cardiovascular translational research · 2026Article
- Reply: Refining the Prognostic Interpretation of Myocardial PD-L1 Expression in ICI-Associated Myocarditis.JACC. CardioOncology · 2026Article
- Cardiac-targeting peptide-modified Prussian blue nanozymes loaded with Astragaloside IV for efficient ICI-myocarditis therapy.Materials today. Bio · 2026Article
- PD-1/PD-L1 inhibitor induces systemic inflammation and alters cardiac lipid metabolism in C57BL/6 J mice.Human cell · 2026Article
- Myocardial Immune Niches in Homeostasis and Inflammation.Immunological reviews · 2026Review
- Heterogeneity of macrophages in PD-1/PD-L1 inhibitor therapy: a single-cell perspective.Cellular & molecular biology letters · 2026Review
64 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Update of
Authors and funding
21 authors at 8 institutions in 3 countries.
Pan MaCardiovascular Division, Department of Medicine (P.M., J.L., A.B., G.B., G.F., J.J., R.H., A.P., J.A., K.J.L.), Washington University School of Medicine, St Louis, MO.ORCID 0000-0002-0815-849X
Jing LiuCardiovascular Division, Department of Medicine (P.M., J.L., A.B., G.B., G.F., J.J., R.H., A.P., J.A., K.J.L.), Washington University School of Medicine, St Louis, MO.ORCID 0000-0002-9666-9133
Juan QinDivision of Cardiology, Department of Medicine, University of California San Francisco (J.Q., J.M.).ORCID 0000-0002-0821-6290
Lulu LaiDepartment of Pathology and Immunology (L.L., A.V., C.-Y.L., K.J.L.), Washington University School of Medicine, St Louis, MO.ORCID 0000-0002-3352-9467
Gyu Seong HeoMallinckrodt Institute of Radiology (G.S.H., H.L., D.S., Y.L.), Washington University School of Medicine, St Louis, MO.ORCID 0000-0001-6200-4742
Hannah LuehmannDepartment of Pathology and Immunology (L.L., A.V., C.-Y.L., K.J.L.), Washington University School of Medicine, St Louis, MO.
Deborah SultanMallinckrodt Institute of Radiology (G.S.H., H.L., D.S., Y.L.), Washington University School of Medicine, St Louis, MO.
Andrea BredemeyerCardiovascular Division, Department of Medicine (P.M., J.L., A.B., G.B., G.F., J.J., R.H., A.P., J.A., K.J.L.), Washington University School of Medicine, St Louis, MO.
Geetika BajapaCardiovascular Division, Department of Medicine (P.M., J.L., A.B., G.B., G.F., J.J., R.H., A.P., J.A., K.J.L.), Washington University School of Medicine, St Louis, MO.
Guoshuai FengCardiovascular Division, Department of Medicine (P.M., J.L., A.B., G.B., G.F., J.J., R.H., A.P., J.A., K.J.L.), Washington University School of Medicine, St Louis, MO.ORCID 0000-0003-3951-0975
Jesus JimenezCardiovascular Division, Department of Medicine (P.M., J.L., A.B., G.B., G.F., J.J., R.H., A.P., J.A., K.J.L.), Washington University School of Medicine, St Louis, MO.
Ruijun HeCardiovascular Division, Department of Medicine (P.M., J.L., A.B., G.B., G.F., J.J., R.H., A.P., J.A., K.J.L.), Washington University School of Medicine, St Louis, MO.
Antanisha ParksCardiovascular Division, Department of Medicine (P.M., J.L., A.B., G.B., G.F., J.J., R.H., A.P., J.A., K.J.L.), Washington University School of Medicine, St Louis, MO.ORCID 0000-0001-5985-6776
Junedh AmruteCardiovascular Division, Department of Medicine (P.M., J.L., A.B., G.B., G.F., J.J., R.H., A.P., J.A., K.J.L.), Washington University School of Medicine, St Louis, MO.ORCID 0000-0002-6851-0168
Ana VillanuevaDepartment of Pathology and Immunology (L.L., A.V., C.-Y.L., K.J.L.), Washington University School of Medicine, St Louis, MO.ORCID 0000-0002-6637-3745
Yongjian LiuMallinckrodt Institute of Radiology (G.S.H., H.L., D.S., Y.L.), Washington University School of Medicine, St Louis, MO.ORCID 0000-0002-1118-1535
Chieh-Yu LinDepartment of Pathology and Immunology (L.L., A.V., C.-Y.L., K.J.L.), Washington University School of Medicine, St Louis, MO.ORCID 0000-0002-4269-3234
Matthias MackDepartment of Internal Medicine II - Nephrology, Universitatsklinikum Regensburg Klinik und Poliklinik Innere Medizin II, Regensburg, Germany (M.M.).
Kaushik AmancherlaDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN (K.A.).ORCID 0000-0003-3379-5834
Javid MoslehiDivision of Cardiology, Department of Medicine, University of California San Francisco (J.Q., J.M.).ORCID 0000-0001-5443-4312
Kory J LavineCardiovascular Division, Department of Medicine (P.M., J.L., A.B., G.B., G.F., J.J., R.H., A.P., J.A., K.J.L.), Washington University School of Medicine, St Louis, MO.ORCID 0000-0003-1948-9945
Jisc · GBWashington University in St. Louis · USMallinckrodt (United States) · USJDSU (United States) · USUniversity of California, San Francisco · USMACOM (United States) · USUniversity Hospital Regensburg · DEVanderbilt University Medical Center · US
Funding
Training/DisseminationP41EB025815 · NIBIB · WASHINGTON UNIVERSITY · PI Robert J. Gropler · 2018 to 2026
$12.7MWashington University Rheumatic DiseasesResearch Resource-based CenterP30AR073752 · NIAMS · WASHINGTON UNIVERSITY · PI Alfred Hyoungju Kim · 2018 to 2026
$7.6MTargeted Molecular Probes for Atherosclerosis Imaging and TherapyR35HL145212 · NHLBI · WASHINGTON UNIVERSITY · PI LIU, YONGJIAN · 2019 to 2025
$5.1MImmunologic and Antigenic Drivers of Immune Checkpoint Inhibitor-Associated MyocarditisR01HL156021 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI Justin M Balko, Javid J Moslehi · 2021 to 2026
$4.9MSpecification and Function of Tissue Resident and Recruited Macrophages in Cardiac Remodeling and Heart FailureR35HL161185 · NHLBI · WASHINGTON UNIVERSITY · PI Kory J. Lavine · 2022 to 2026
$4.3MPediatric Cardiovascular and Pulmonary Research Training Program.T32HL125241 · NHLBI · WASHINGTON UNIVERSITY · PI Juliane Bubeck Wardenburg, Kory J. Lavine · 2015 to 2026
$4.1MMolecular Imaging CCR2 Lung Inflammation and FibrosisR01HL151685 · NHLBI · WASHINGTON UNIVERSITY · PI BRODY, STEVEN · 2021 to 2025
$3.7MPET Detection of CCR2 in Human AtherosclerosisR01HL150891 · NHLBI · WASHINGTON UNIVERSITY · PI GROPLER, ROBERT J., WOODARD, PAMELA K · 2020 to 2024
$3.7M[18F]F-AraG as an imaging biomarker for early diagnosis and monitoring of cardiotoxicity related to doxorubicin and immune check point inhibitor therapyR01HL160688 · NHLBI · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI Jelena Levi, Youngho Seo · 2022 to 2026
$3.4MNovel mechanisms and predictors of VEGF receptor inhibitor-associated hypertensionR01HL141466 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI MOSLEHI, JAVID J · 2019 to 2023
$3.3MLong-Term Cardiovascular Sequelae of Cancer ImmunotherapiesR01HL155990 · NHLBI · VANDERBILT UNIVERSITY MEDICAL CENTER · PI JOHNSON, DOUGLAS B, MOSLEHI, JAVID J · 2021 to 2025
$3.3MCCR2 Targeted Molecular Imaging and Treatment of Abdominal Aortic AneurysmsR01HL153436 · NHLBI · WASHINGTON UNIVERSITY · PI GROPLER, ROBERT J., ZAYED, MOHAMED A. · 2020 to 2023
$3.0MNHLBI NIH HHS R01 HL131908NHLBI NIH HHS R01 HL138466NHLBI NIH HHS R01 HL139714NHLBI NIH HHS R01 HL141466NHLBI NIH HHS R01 HL150891NHLBI NIH HHS R01 HL151078NHLBI NIH HHS R01 HL151685NHLBI NIH HHS R01 HL153436NHLBI NIH HHS R01 HL155990NHLBI NIH HHS R01 HL156021NHLBI NIH HHS R01 HL160688NHLBI NIH HHS R35 HL145212NHLBI NIH HHS R35 HL161185NHLBI NIH HHS T32 HL125241NIAMS NIH HHS P30 AR073752NIBIB NIH HHS P41 EB025815
Abstract
backgroundImmune checkpoint inhibitors (ICIs), antibodies targeting PD-1 (programmed cell death protein 1)/PD-L1 (programmed death-ligand 1) or CTLA4 (cytotoxic T-lymphocyte-associated protein 4), have revolutionized cancer management but are associated with devastating immune-related adverse events including myocarditis. The main risk factor for ICI myocarditis is the use of combination PD-1 and CTLA4 inhibition. ICI myocarditis is often fulminant and is pathologically characterized by myocardial infiltration of T lymphocytes and macrophages. Although much has been learned about the role of T-cells in ICI myocarditis, little is understood about the identity, transcriptional diversity, and functions of infiltrating macrophages.
methodsWe used an established murine ICI myocarditis model (
resultsWe observed marked increases in CCR2 (C-C chemokine receptor type 2)
conclusionsThese data demonstrate that ICI myocarditis is associated with the expansion of a specific population of IFN-γ-induced inflammatory macrophages and suggest the possibility that IFN-γ blockade may be considered as a treatment option for this devastating condition.
Indexed as
Immune Checkpoint InhibitorsMyocarditisAnimalsCD8-Positive T-LymphocytesChemokinesCTLA-4 AntigenHumansLigandsMacrophagesMiceProgrammed Cell Death 1 ReceptorRNAChemokinesCTLA-4 AntigenImmune Checkpoint InhibitorsLigandsProgrammed Cell Death 1 ReceptorRNACXCL9 chemokinecytotoxic T lymphocyte-associated antigen 4-immunoglobulinIFN-gammamacrophagesmyocarditisprogrammed cell death protein 1T-cells
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.